Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Lowered to $70.00 at JPMorgan Chase & Co.

Posted by George Bondi on Sep 22nd, 2026

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) had its price target dropped by JPMorgan Chase & Co. from $76.00 to $70.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 55.90% from the company’s previous close.

Several other equities research analysts also recently issued reports on the stock. Canaccord Genuity Group decreased their price objective on shares of Ionis Pharmaceuticals from $95.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, September 8th. Wells Fargo & Company lowered their price target on Ionis Pharmaceuticals from $100.00 to $95.00 and set an “overweight” rating for the company in a report on Thursday, July 30th. Needham & Company LLC reissued a “buy” rating and issued a $86.00 price objective on shares of Ionis Pharmaceuticals in a research report on Friday, September 4th. Royal Bank Of Canada decreased their target price on Ionis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Finally, Wall Street Zen lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. Seventeen research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $90.50.

Check Out Our Latest Stock Report on IONS

Ionis Pharmaceuticals Stock Up 1.0%

IONS opened at $44.90 on Tuesday. The firm has a 50 day moving average price of $55.73 and a 200 day moving average price of $68.07. The company has a market cap of $7.46 billion, a PE ratio of -12.98 and a beta of 0.42. Ionis Pharmaceuticals has a 1 year low of $44.20 and a 1 year high of $86.74. The company has a debt-to-equity ratio of 3.07, a quick ratio of 7.73 and a current ratio of 7.89.

Insider Activity at Ionis Pharmaceuticals

In related news, EVP C. Bennett sold 15,000 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $85.46, for a total value of $1,281,900.00. Following the sale, the executive vice president directly owned 75,018 shares of the company’s stock, valued at $6,411,038.28. This represents a 16.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Eric Swayze sold 10,602 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $79.18, for a total transaction of $839,466.36. Following the transaction, the executive vice president owned 21,759 shares in the company, valued at $1,722,877.62. This trade represents a 32.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 156,317 shares of company stock worth $12,656,566. 1.81% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Handelsbanken Fonder AB raised its stake in Ionis Pharmaceuticals by 79.1% during the 2nd quarter. Handelsbanken Fonder AB now owns 383,211 shares of the company’s stock valued at $30,385,000 after purchasing an additional 169,300 shares during the period. Empowered Funds LLC boosted its position in shares of Ionis Pharmaceuticals by 318.1% in the first quarter. Empowered Funds LLC now owns 103,141 shares of the company’s stock worth $7,745,000 after buying an additional 78,470 shares during the period. Perceptive Advisors LLC purchased a new position in shares of Ionis Pharmaceuticals during the first quarter valued at $37,845,000. TimesSquare Capital Management LLC acquired a new position in Ionis Pharmaceuticals during the second quarter valued at $48,690,000. Finally, Eagle Health Investments LP acquired a new position in Ionis Pharmaceuticals during the second quarter valued at $15,428,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

About Ionis Pharmaceuticals

(Get Free Report)

Ionis Pharmaceuticals, Inc is a biotechnology company that discovers and develops medicines using antisense technology, which is designed to target RNA and influence the production of disease-related proteins. The company focuses on neurological, cardiovascular, metabolic and other serious diseases for which there remains a significant unmet medical need.

Ionis has developed several approved therapies, including SPINRAZA (nusinersen) for spinal muscular atrophy, QALSODY (tofersen) for a form of amyotrophic lateral sclerosis, TEGSEDI (inotersen) for hereditary transthyretin-mediated amyloidosis and WAYLIVRA (volanesorsen) for familial chylomicronemia syndrome in certain markets.